Billed as "the single most influential and wide-ranging dialogue about liver disease in the world," The Liver MeetingÂ® is "the premier Annual Meeting in the science and practice of hepatology, including the latest findings on new drugs, novel treatments, and the results from pilot and multicenter studies."
Drawing upon data from a large European study, AndrÃ©s CÃ¡rdenas, MD, reported an association between hyponatremia and acute-on-chronic liver failure (ACLF) during a poster session at the 2013 annual meeting of the American Association for the Study of Liver Diseases held November 1-5, 2013, in Washington, DC.
Investigating the association between hyponatremia and cognition in patients with cirrhosis, Jasmohan Bajaj, MD, and colleagues from Virginia Commonwealth University presented results showing reduced brain edema, better quality of life (QOL), and less caregiver burden with the use of the aquaretic tolvaptan.
Emerging data from a clinical trial on triple direct-acting antiviral (DAA) therapy plus ribavirin (RBV) in hepatitis C (HCV) genotype 1 (GT1) patients shows that the low rate of relapse during and after treatment leads to high concordance rates between measurements of sustained viral response (SVR) at 4, 12, and 24 weeks post-treatment.
Novel Interferon-Free Regimen for Hepatitis C Produces High Treatment Adherence, Sustained Viral Response
Extended Triple Therapy After Liver Transplant Improves Hepatitis C Virologic Response, But at a Cost of Toxicity
Initiating Treatment for Hepatitis C Genotype 1 Before Progression to Cirrhosis May Reduce Liver Complications